Table 1.

Clinical and pathological characteristics of matched samples in UGT groups.

Characteristics	Controlsa	UGT2B17 KOb	UGT2B28 KOc
	n = 30	n = 30	n = 24
Mean age at diagnosis ± SD (years)	61.7 ± 5.6	64.0 ± 4.9	62.6 ± 5.6
Range	51.7–70.7	53.8–73.4	53.7–73.7
PSA at diagnosis ± SD (ng/ml)	7.4 ± 7.5	7.0 ± 5.0	7.6 ± 4.7
Range	2.3–45.4	1.2–21.0	3.9–24.2
	n (%)	n (%)	n (%)
Pathologic Gleason score
<7	6 (20%)	7 (23%)	5 (21%)
7	23 (77%)	22 (74%)	18 (75%)
>7	1 (3%)	1 (3%)	1 (4%)
Pathologic T stage
<pT3a	15 (50%)	18 (60%)	13 (54%)
pT3a	13 (43%)	10 (33%)	9 (38%)
>pT3a	2 (7%)	2 (7%)	2 (8%)

^aSubjects carrying both copies of the UGT2B17 and UGT2B28 genes.

^bSubjects homozygous for UGT2B17 gene deletion (KO) and carrying both copies of the UGT2B28 gene

^cSubjects carrying both copies of the UGT2B17 gene and homozygous for UGT2B28 gene deletion (KO).

PSA: prostate serum antigen at diagnosis; age at PCa diagnosis.